^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Immunosuppressant

    Related drugs:
    3d
    CD45RA-depleted CD19-CAR T Cell Consolidation After TCR??+ T Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, St. Jude Children's Research Hospital
    New P1 trial
    |
    cyclophosphamide • melphalan • fludarabine IV • thiotepa • Neupogen (filgrastim)
    4d
    The burden of skin cancer in heart transplant recipients: Impact of immunosuppressive regimens. (PubMed, JHLT Open)
    Immunosuppression with calcineurin inhibitor (CNI) plus azathioprine (AZA) was independently associated with increased skin cancer risk (odds ratio [OR] 9.41, p = 0.044), especially for SCC (OR 6.6, p = 0.027)...Skin cancer is a relevant long-term complication after HTx, particularly SCC in patients receiving AZA. Our findings support limiting AZA use and reinforce the importance of structured dermatologic surveillance and early mammalian target of rapamycin conversion strategies to improve long-term outcomes.
    Journal
    |
    mTOR (Mechanistic target of rapamycin kinase)
    6d
    Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between TPMT/NUDT15 and thiopurines. (PubMed, Eur J Hum Genet)
    The current guideline describes the gene-drug interactions for TPMT, NUDT15 and thiopurines (azathioprine, 6-mercaptopurine and thioguanine). For TPMT or NUDT15 IM treated for leukaemia, starting with the normal dose can be considered and then decrease the dose to the advised dose described above in case toxicities occur. For NUDT15 PM reduced starting dose is advised only if an alternative is not possible, due to a higher uncertainty in the calculated dose reduction for NUDT15 PM than for TPMT PM.DPWG classifies genotyping for TPMT and NUDT15 "essential" before thiopurine initiation.
    Journal
    |
    NUDT15 (Nudix Hydrolase 15)
    |
    mercaptopurine • thioguanine
    7d
    ABX464-103: Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis (clinicaltrials.gov)
    P2, N=355, Completed, Abivax S.A. | Phase classification: P2b --> P2 | N=254 --> 355
    Phase classification • Enrollment change
    |
    mercaptopurine
    9d
    Precision Administration of Anti-thymocyte Globulin With or Without Verapamil (clinicaltrials.gov)
    P2, N=60, Recruiting, University of Florida | Not yet recruiting --> Recruiting
    Enrollment open
    10d
    Niosomal mefloquine and cisplatin in breast cancer: comparative effects on apoptosis and angiogenesis via in vitro and in silico analysis. (PubMed, BMC Cancer)
    The niosomal formulation of MEF synergistically enhances CIS efficacy by promoting apoptosis, and suppressing angiogenesis in TNBC. These findings highlight NMEF as a promising chemosensitizer to overcome cisplatin resistance. Future studies should focus on in vivo validation and clinical translation.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • KDR (Kinase insert domain receptor) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
    |
    cisplatin
    10d
    IDEA: Discontinuation of Thiopurine Therapy in Elderly Patients With Ulcerative Colitis (clinicaltrials.gov)
    P4, N=304, Not yet recruiting, Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
    New P4 trial
    11d
    WAVE T1D: A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (clinicaltrials.gov)
    P1/2, N=120, Not yet recruiting, City of Hope Medical Center | Initiation date: Jan 2026 --> Dec 2026
    Trial initiation date
    14d
    A Study of Auxora in Patients With Critical COVID-19 Pneumonia (clinicaltrials.gov)
    P2, N=10, Terminated, CalciMedica, Inc. | Completed --> Terminated; The trial was terminated early due to the limited number of new COVID-19 hospitalizations.
    Trial termination
    15d
    Photobiomodulation in Combination With Topical Cyclosporine A or Tacrolimus (clinicaltrials.gov)
    P1, N=160, Completed, University of Seville
    New P1 trial
    16d
    WAVE T1D: A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (clinicaltrials.gov)
    P1/2, N=120, Not yet recruiting, City of Hope Medical Center | Initiation date: Oct 2025 --> Jan 2026
    Trial initiation date
    17d
    Neuro-KTR: Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients (clinicaltrials.gov)
    P4, N=92, Not yet recruiting, Massachusetts General Hospital | Initiation date: May 2025 --> Dec 2025
    Trial initiation date